| Treatment with a farnesyltransferase inhibitor improves survival in mice with a Hutchinson-Gilford progeria syndrome mutation. | |
| | |
MedLine Citation:
|
PMID: 18082640 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Hutchinson-Gilford progeria syndrome (HGPS) is a progeroid syndrome characterized by multiple aging-like disease phenotypes. We recently reported that a protein farnesyltransferase inhibitor (FTI) improved several disease phenotypes in mice with a HGPS mutation (Lmna(HG/+)). Here, we investigated the impact of an FTI on the survival of Lmna(HG/+) mice. The FTI significantly improved the survival of both male and female Lmna(HG/+) mice. Treatment with the FTI also improved body weight curves and reduced the number of spontaneous rib fractures. This study provides further evidence for a beneficial effect of an FTI in HGPS. |
| | |
Authors:
|
Shao H Yang; Xin Qiao; Loren G Fong; Stephen G Young |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't Date: 2007-11-26 |
Journal Detail:
|
Title: Biochimica et biophysica acta Volume: 1781 ISSN: 0006-3002 ISO Abbreviation: Biochim. Biophys. Acta Publication Date: 2008 Jan-Feb |
Date Detail:
|
Created Date: 2008-02-11 Completed Date: 2008-04-04 Revised Date: 2011-01-10 |
Medline Journal Info:
|
Nlm Unique ID: 0217513 Medline TA: Biochim Biophys Acta Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 36-9 Citation Subset: IM |
Affiliation:
|
Department of Medicine/Division of Cardiology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Farnesyltranstransferase / antagonists & inhibitors*, metabolism Female Lamin Type A / genetics, metabolism Male Mice Mice, Inbred C57BL Mice, Transgenic Mutation Phenotype Progeria / drug therapy*, enzymology, genetics* Survival Rate |
| Grant Support | |
ID/Acronym/Agency:
|
AR050200/AR/NIAMS NIH HHS; HL76839/HL/NHLBI NIH HHS; HL86683/HL/NHLBI NIH HHS; R01 AR050200-01/AR/NIAMS NIH HHS; R01 AR050200-02/AR/NIAMS NIH HHS; R01 AR050200-02S1/AR/NIAMS NIH HHS; R01 AR050200-03/AR/NIAMS NIH HHS; R01 AR050200-04/AR/NIAMS NIH HHS; R01 AR050200-05/AR/NIAMS NIH HHS; R01 AR050200-06/AR/NIAMS NIH HHS; R01 HL076839-01A1/HL/NHLBI NIH HHS; R01 HL076839-02/HL/NHLBI NIH HHS; R01 HL076839-03/HL/NHLBI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Lamin Type A; EC 2.5.1.29/Farnesyltranstransferase |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: trans-Arachidonic acids induce a heme oxygenase-dependent vasorelaxation of cerebral microvasculatur...
Next Document: A quantitative and morphometric study of tryptase-positive mast cells in cutaneous leprosy lesions.